Merck Sharp + Dohme Corp.

Jounce Therapeutics, Inc.

Heather Hirsch

Terrill K McClanahan

Michael V Nebozhyn

Sriram Sathyanarayanan

Mark David Ayers

Christopher Harvey

Andrey Loboda

Stephen Sazinsky

Jennifer S Michaelson

Kutlu Goksu Elpek

Jared K Lunceford

Lauren Pepper MacKenzie

Amit Deshpande

Jason Windham Reeves

Igor Feldman

Terrill K Mcclanahan

Jared Lunceford

The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Blood-based biomarkers of tumor sensitivity to PD-1 antagonists

Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.

Gene signatures for determining ICOS expression

Growing community of inventors

Brookline, MA, United States of America

Heather Hirsch